Profusa Inc. Swaps $1.87 M Convertible Note for 5.34 M Shares, Fuels Quiet Insider Buying Spree Ahead of Potential IPO or Merger.

Insider Activity Highlights a Strategic Shift at Profusa Inc. The most recent filing on May 4, 2026 shows a conversion of a $1.87 million convertible promissory note into 5.34 million shares of common stock. The transaction, executed through a related entity, dilutes existing shareholders but also signals a deepening of the company’s capital structure. The conversion price is pegged to a floor of $0.35, ensuring that the newly issued shares do not fall below a modest valuation threshold. While the share price at the time of the transaction was $0.44, the conversion has added fresh liquidity and may serve as a precursor to a larger fundraising effort.

Implications for Investors and the Company’s Future The conversion occurs against a backdrop of a steeply falling share price – a 52‑week low of $0.41 and an annual decline of nearly 100 %. The dilution from the note conversion could further compress earnings per share, yet the influx of capital may fund product development, regulatory approvals, or a strategic acquisition. For investors, the move warrants a watchful eye: the dilution risk is counterbalanced by the potential for the company to achieve a higher valuation once it completes its planned transaction and stabilizes its cash flow. The timing of the conversion, aligned with the effective filing of a pending S‑1, suggests that Profusa is positioning itself for an eventual public offering or a merger that could unlock shareholder value.

A Look Back at STOVER JACK E’s Trading Pattern Owner STOVER JACK E has been an active participant in Profusa’s insider market since January 2026. In a single day (January 26), the individual purchased 221,794 stock options, 52,866 options, 553,665 common shares, and 380,280 warrants, amounting to a total of 1,368,585 shares and warrants. These trades were executed at zero cost for options and warrants, indicating that the owner was exercising grants rather than purchasing on the open market. The pattern shows a willingness to take long positions in both equity and derivative instruments, suggesting a bullish stance on the company’s prospects. However, the lack of any recorded sales by STOVER JACK E in the period analyzed raises questions about the liquidity of his holdings and whether he is positioning for a future exit.

Company‑Wide Insider Activity: A Broader Context Other insiders, notably CFO Fred S. Knechtel and NorthView Sponsor I, LLC, have also been active. Knechtel’s purchases of 818,961 shares and 516,863 warrants, coupled with the sponsor’s sizeable share and warrant transactions, indicate a coordinated effort among key stakeholders to align their interests with the company’s long‑term trajectory. The simultaneous buying and selling activity by the sponsor—selling 4,743,750 shares and buying 5,162,500 warrants—could be a strategic realignment of ownership stakes, perhaps in anticipation of a future transaction or a shift in control dynamics.

What Should Investors Watch?

1. Capital Deployment – How Profusa plans to use the proceeds from the note conversion and any subsequent offerings.
2. Regulatory Milestones – Completion of the pending S‑1 and any forthcoming filings that could trigger a liquidity event.
3. Shareholder Alignment – The extent to which insiders continue to accumulate or divest shares, which can be a proxy for confidence in the company’s strategy.
4. Market Sentiment – Although current buzz is neutral and price movement minimal, the ongoing negative trend in share price suggests that external factors (e.g., sector headwinds in health care or challenges in the SPAC space) could impact valuation.

In sum, Profusa’s recent insider transaction reflects a deliberate infusion of capital and a potential pivot toward a larger transaction. While the dilution effect is immediate, the long‑term impact will hinge on the company’s ability to convert this capital into sustainable growth and a credible exit strategy for its shareholders.